News
-
-
-
COMMUNIQUÉ DE PRESSE
Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
Menarini Group presents updated Phase 2 combination data of Elacestrant in ER+, HER2- metastatic breast cancer patients at 2025 San Antonio Breast Cancer Symposium, showing promising progression-free survival benefits and safety profiles -
-
-
COMMUNIQUÉ DE PRESSE
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
Menarini Group and Stemline Therapeutics to present new data on ELZONRIS at ASH Annual Meeting. Data includes triplet therapy results for BPDCN patients -
-
-
